ABVX Abivax SA

ABIVAX annonce la mise à disposition de son Rapport Financier Semestriel 2016

PARIS--(BUSINESS WIRE)--

Regualtory News:

ABIVAX (Paris:ABVX) (Euronext Paris : FR0012333284 – ABVX), société de biotechnologie ciblant le système immunitaire pour éliminer des maladies virales, annonce avoir deposé ce jour son Rapport Financier Semestriel 2016 auprès des marchés financiers (AMF). Ce document est disponible en version électronique sur le site internet de la société (www.abivax.com) et sur le site de l’AMF (www.amf-france.org).

A propos d'ABIVAX (www.abivax.com)

ABIVAX est une société innovante de biotechnologie qui cible le système immunitaire pour éliminer des maladies virales. ABIVAX dispose de trois plateformes technologiques : une plateforme « anti-virale », une plateforme « stimulation immunitaire » et une plateforme « anticorps polyclonaux ». Son produit le plus avancé, ABX464, est une nouvelle molécule prometteuse contre le VIH/SIDA, administrée par voie orale, à l’épreuve des résistances développées par le virus. ABIVAX développe également plusieurs candidats médicaments contre des virus additionnels et un candidat stimulateur immunitaire, dont plusieurs sont susceptibles d’entrer en phase de développement clinique dans les 18 prochains mois (Chikungunya, Ebola, Dengue, etc.). ABIVAX est cotée sur le compartiment B d’Euronext à Paris (ISIN : FR0012333284 – Mnémo : ABVX). Plus d'informations sur : www.abivax.com

Suivez-nous sur Twitter @ABIVAX

FR
20/09/2016

Underlying

ABVXAbivax SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abivax SA

 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax to be Added to Nasdaq Biotechnology Index

Abivax to be Added to Nasdaq Biotechnology Index Abivax to be Added to Nasdaq Biotechnology Index PARIS, France – December 18, 2025 – 10:05 pm CET – (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 22, 2025. Didie...

17h / 55m 1 EN
 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in I...

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific Evidence: The acceptance of 1 oral presentation, 5 digital oral presentations and 16 posters reflect an expanding dataset for obefazimod, including additional efficacy, safety, and cytokine data from the Phase 3 ABTE...

December 17, 2025 1 EN
 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax Presents Third Quarter 2025 Financial Results

Abivax Presents Third Quarter 2025 Financial Results Abivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with a cash runway into Q4 2027 PARIS, France, December 15, 2025, 10:05 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced today its key financial info...

December 15, 2025 1 EN
 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTEC...

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis Improvements across all patient reported outcomes (PROs) were observed from baseline to Week 8 in all PRO instruments utilized in the ABTECT ...

November 3, 2025 1 EN
Free Trial
ABVX ABIVAX SA

Abivax: 1 director

A director at Abivax sold 1,200,000 shares at 94.085EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

11/01/25 November 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch